Agilent Technologies Debt to Equity Ratio 2010-2025 | A
Current and historical debt to equity ratio values for Agilent Technologies (A) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Agilent Technologies debt/equity for the three months ending April 30, 2025 was 0.55.
| Agilent Technologies Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-04-30 | $6.02B | $6.14B | 0.98 |
| 2025-01-31 | $5.89B | $6.03B | 0.98 |
| 2024-10-31 | $5.95B | $5.90B | 1.01 |
| 2024-07-31 | $5.09B | $5.90B | 0.86 |
| 2024-04-30 | $4.64B | $6.21B | 0.75 |
| 2024-01-31 | $4.76B | $6.19B | 0.77 |
| 2023-10-31 | $4.92B | $5.85B | 0.84 |
| 2023-07-31 | $5.12B | $5.56B | 0.92 |
| 2023-04-30 | $5.01B | $5.78B | 0.87 |
| 2023-01-31 | $5.31B | $5.61B | 0.95 |
| 2022-10-31 | $5.23B | $5.31B | 0.99 |
| 2022-07-31 | $5.39B | $5.09B | 1.06 |
| 2022-04-30 | $5.33B | $5.12B | 1.04 |
| 2022-01-31 | $5.17B | $5.15B | 1.00 |
| 2021-10-31 | $5.32B | $5.39B | 0.99 |
| 2021-07-31 | $5.55B | $4.95B | 1.12 |
| 2021-04-30 | $5.59B | $4.81B | 1.16 |
| 2021-01-31 | $4.87B | $4.80B | 1.01 |
| 2020-10-31 | $4.75B | $4.87B | 0.98 |
| 2020-07-31 | $4.57B | $4.98B | 0.92 |
| 2020-04-30 | $4.69B | $4.77B | 0.98 |
| 2020-01-31 | $4.65B | $4.85B | 0.96 |
| 2019-10-31 | $4.70B | $4.75B | 0.99 |
| 2019-07-31 | $3.88B | $4.75B | 0.82 |
| 2019-04-30 | $3.90B | $5.13B | 0.76 |
| 2019-01-31 | $3.92B | $5.04B | 0.78 |
| 2018-10-31 | $3.97B | $4.57B | 0.87 |
| 2018-07-31 | $3.78B | $4.57B | 0.83 |
| 2018-04-30 | $4.17B | $4.62B | 0.90 |
| 2018-01-31 | $4.17B | $4.53B | 0.92 |
| 2017-10-31 | $3.59B | $4.84B | 0.74 |
| 2017-07-31 | $3.65B | $4.61B | 0.79 |
| 2017-04-30 | $3.64B | $4.38B | 0.83 |
| 2017-01-31 | $3.57B | $4.30B | 0.83 |
| 2016-10-31 | $3.55B | $4.25B | 0.84 |
| 2016-07-31 | $3.39B | $4.35B | 0.78 |
| 2016-04-30 | $3.48B | $4.17B | 0.83 |
| 2016-01-31 | $3.25B | $4.05B | 0.80 |
| 2015-10-31 | $3.31B | $4.17B | 0.79 |
| 2015-07-31 | $3.15B | $4.11B | 0.77 |
| 2015-04-30 | $3.25B | $4.16B | 0.78 |
| 2015-01-31 | $3.28B | $4.24B | 0.77 |
| 2014-10-31 | $5.51B | $5.30B | 1.04 |
| 2014-07-31 | $4.74B | $5.64B | 0.84 |
| 2014-04-30 | $5.40B | $5.63B | 0.96 |
| 2014-01-31 | $5.19B | $5.45B | 0.95 |
| 2013-10-31 | $5.40B | $5.29B | 1.02 |
| 2013-07-31 | $5.49B | $4.79B | 1.15 |
| 2013-04-30 | $5.28B | $5.31B | 1.00 |
| 2013-01-31 | $5.30B | $5.35B | 0.99 |
| 2012-10-31 | $5.35B | $5.19B | 1.03 |
| 2012-07-31 | $4.88B | $4.87B | 1.00 |
| 2012-04-30 | $4.69B | $4.73B | 0.99 |
| 2012-01-31 | $4.60B | $4.50B | 1.02 |
| 2011-10-31 | $4.74B | $4.32B | 1.10 |
| 2011-07-31 | $4.55B | $4.20B | 1.08 |
| 2011-04-30 | $4.69B | $3.96B | 1.18 |
| 2011-01-31 | $4.71B | $3.34B | 1.41 |
| 2010-10-31 | $6.46B | $3.24B | 2.00 |
| 2010-07-31 | $6.29B | $2.81B | 2.24 |
| 2010-04-30 | $5.14B | $2.63B | 1.95 |
| 2010-01-31 | $4.98B | $2.60B | 1.92 |
| 2009-10-31 | $5.10B | $2.51B | 2.03 |
| 2009-07-31 | $4.08B | $2.49B | 1.64 |
| 2009-04-30 | $4.16B | $2.42B | 1.72 |
| 2009-01-31 | $4.59B | $2.57B | 1.79 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $32.378B | $6.510B |
| Agilent Technologies, Inc. is an original equipment manufacturer of a broad-based portfolio of test and measurement products serving multiple end markets. Recently, the company has diversified into new end markets, namely industrial, chemical and electronics markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG).The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers' representatives, telesales and electronic commerce, as necessary. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.845B | 26.95 |
| Boston Scientific (BSX) | United States | $152.561B | 36.38 |
| Stryker (SYK) | United States | $143.889B | 29.29 |
| EssilorLuxottica (ESLOY) | France | $136.285B | 0.00 |
| Medtronic (MDT) | Ireland | $116.952B | 16.59 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.016B | 0.00 |
| Haleon (HLN) | United Kingdom | $42.497B | 24.26 |
| ResMed (RMD) | United States | $41.081B | 29.34 |
| GE HealthCare Technologies (GEHC) | United States | $32.462B | 15.26 |
| Terumo (TRUMY) | Japan | $27.642B | 32.75 |
| Koninklijke Philips (PHG) | Netherlands | $25.623B | 16.95 |
| Insulet (PODD) | United States | $21.362B | 71.59 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.474B | 12.41 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.802B | 0.00 |
| Baxter (BAX) | United States | $12.091B | 9.34 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.599B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.179B | 26.37 |
| Lantheus Holdings (LNTH) | United States | $3.730B | 10.09 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.341B | 14.76 |
| Envista Holdings (NVST) | United States | $3.339B | 23.36 |
| ICU Medical (ICUI) | United States | $3.197B | 21.83 |
| Perrigo (PRGO) | Ireland | $3.141B | 7.85 |
| Haemonetics (HAE) | United States | $2.673B | 11.96 |
| LeMaitre Vascular (LMAT) | United States | $2.134B | 45.76 |
| AtriCure (ATRC) | United States | $1.784B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.657B | 10.43 |
| Green Thumb Industries (GTBIF) | United States | $1.478B | 63.46 |
| AdaptHealth (AHCO) | United States | $1.252B | 17.85 |
| Curaleaf Holdings (CURLF) | Canada | $1.200B | 0.00 |
| Acuren (TIC) | United States | $1.180B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.108B | 14.16 |
| Neogen (NEOG) | United States | $1.086B | 17.24 |
| BioLife Solutions (BLFS) | United States | $0.987B | 2064.00 |
| InMode (INMD) | Israel | $0.908B | 8.40 |
| Kestra Medical Technologies (KMTS) | United States | $0.757B | 0.00 |
| Valneva SE (VALN) | France | $0.702B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.655B | 0.00 |
| ZimVie (ZIMV) | United States | $0.532B | 20.49 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.516B | 0.00 |
| Surmodics (SRDX) | United States | $0.501B | 0.00 |
| Owens & Minor (OMI) | United States | $0.487B | 4.04 |
| CeriBell (CBLL) | United States | $0.461B | 0.00 |
| SNDL (SNDL) | Canada | $0.439B | 0.00 |
| Evolus (EOLS) | United States | $0.393B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.369B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.334B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.322B | 11.16 |
| Verano Holdings (VRNOF) | United States | $0.307B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.294B | 0.00 |
| Quanterix (QTRX) | United States | $0.275B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.270B | 20.47 |
| Cerus (CERS) | United States | $0.238B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.237B | 0.00 |
| Omeros (OMER) | United States | $0.233B | 0.00 |
| Brainsway (BWAY) | Israel | $0.224B | 59.15 |
| Sanara MedTech (SMTI) | United States | $0.217B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.215B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.201B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.200B | 0.00 |
| Exagen (XGN) | United States | $0.198B | 0.00 |
| Organigram Global (OGI) | Canada | $0.189B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.181B | 14.89 |
| High Tide (HITI) | Canada | $0.177B | 0.00 |
| Biote (BTMD) | United States | $0.160B | 4.79 |
| TerrAscend (TSNDF) | Canada | $0.156B | 0.00 |
| Safety Shot (SHOT) | United States | $0.139B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.139B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 16.81 |
| Jushi Holdings (JUSHF) | United States | $0.124B | 0.00 |
| MacroGenics (MGNX) | United States | $0.102B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.098B | 12.63 |
| Quipt Home Medical (QIPT) | United States | $0.093B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Apyx Medical (APYX) | United States | $0.074B | 0.00 |
| Agape ATP (ATPC) | $0.067B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 0.00 |
| Veru (VERU) | United States | $0.055B | 0.00 |
| Zynex (ZYXI) | United States | $0.045B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 12.60 |
| Rockwell Medical (RMTI) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.031B | 24.08 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.010B | 0.00 |
| Flora Growth (FLGC) | United States | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |